Intellectual Property Law

HB Ad Slot
HB Mobile Ad Slot

Intellectual property applies to many different areas of the legal world. Applying for patents for work-products, by individual employees, trademark laws, copyrights, and how companies leverage their IP asset-rights over employees, are just a few of the many areas the National Law Review covers as it pertains to IP.

Intellectual Property Litigation

Intellectual Property disputes are a complex area of law, often involving deep dives into complex concepts to understand the issues at play. In the United States, the United States Patent and Trademark Office (USPTO/PTO) is the agency involved in registering patents and trademarks.   As part of the USPTO, the Patent Trial and Appeal Board settles patent disputes, using a variety of mechanisms to settle issues related to intellectual property.    Some of the mechanisms include inter partes review, post-grant procedures, and covered business method patent reviews.  Issues related to the America Invents Act are also settled through the PTAB. The National Law Review covers changes to standards held by the USPTO in litigation and other patent issues.  The Trademark Trial and Appeal Board settles disputes related to trademarks, such as an ex parte appeal from the denial of an application for registration by an examining attorney, and an inter partes opposition, cancellation, concurrent use, or interference proceeding.  Other agencies involved in patent disputes are the International Trade Commission (ITC) or the Federal Trade Commission (FTC).  The National Law Review covers patent news as it relates to Supreme Court (SCOTUS) and federal circuit courts’ appeals, as well as general patent litigation and new patent filings.

Intellectual Property in Drug Patents

Legal analysis related to drug patents and pharmaceuticals and the interplay with intellectual property issues are also covered by the National Law Review.   Drug patents, biosimilars, generic top-level domain registration (gTLD), trade secrets, non-compete clauses, and other patent application news are updated on the site regularly. Additionally, tangential issues that impact pharmaceutical companies, such as innovator liability and related litigation, are also analyzed by the legal experts who write for the National Law Review. 

Intellectual Property in an Employment Context

The National Law Review has legal analysis on the intersection between intellectual property rights and employment, and who owns ideas, the Work Made For Hire principle as well resulting litigation. Additionally, legislation such as the Defense of Trade Secrets Act and its impact on workplaces, and ongoing litigation related to the legislation is also covered.

International Intellectual Property

Visitors to the site will oftentimes read about international news as it relates to patent applications in the US, and internationally as well. Pharmaceutical patents in Brazil, medical device patent applications from the United Kingdom, or litigation from the European Union, China, India, and other international sectors, are often covered online. Visitors will find the latest coverage, news, and insights on patent applications and litigation, when visiting the National Law Review, for up-to-date practice-area news.

National Law Review Intellectual Property/Patent Law TwitterFor hourly updates on the latest news about Intellectual Property Law, IP Litigation, Patent Legislation, and more, be sure to follow our IP Law Twitter feed, and sign up for complimentary e-news bulletins.

Recent Intellectual Property, Patent, Trademark & Copyright News

Title
Custom text Organization Sort descending
Jan
19
2016
PTAB Denies Challenge Of Abbvie Humira Patents Foley & Lardner LLP
Jan
29
2016
Split Federal Circuit Upholds Constitutionality of Single PTAB Panels Rendering Both Institution & Final Written Decisions Foley & Lardner LLP
Feb
11
2016
FDA Panel Shows Strong Support for Remicade Biosimilar Foley & Lardner LLP
Oct
25
2023
Navigating the AI Frontier: Legal and Operational Insights Into Generative AI Foley & Lardner LLP
Nov
16
2023
USPTO Expands Eligibility for Design Patent Practitioners Foley & Lardner LLP
Jun
27
2019
Automotive Market Trends | June 2019 Foley & Lardner LLP
Mar
15
2016
PTAB Institutes Kyle Bass IPR Against Pharmaceutical Patent Based On SEC Document Foley & Lardner LLP
Sep
3
2019
Federal Circuit Finds Method Withholding Treatment Ineligible For Patenting Foley & Lardner LLP
Oct
10
2019
Antitrust Surprises from DOJ during the Trump Administration – Predicting the Consequences Foley & Lardner LLP
May
7
2016
USPTO Releases Patent Eligibility Update Foley & Lardner LLP
Jun
13
2016
PTAB Holds Technical Difficulties Will Not Save Late-Filed IPR Petitions Foley & Lardner LLP
Jul
27
2016
Magnum Offers New Path for Challenging AIA Decisions: Burden of Production Foley & Lardner LLP
Jun
15
2020
USPTO Expands CARES Act Relief to Non-Provisional Application Filings Deadlines Foley & Lardner LLP
Jul
30
2020
Coronavirus Innovation Guideposts on the Eve of the COVID-19 Pandemic Foley & Lardner LLP
Sep
17
2020
USPTO Announces New Program To Promote Publication Of COVID-19 Innovation Foley & Lardner LLP
Oct
13
2020
USPTO Publishes Proposed Guidelines On USPTO CLE Credit Foley & Lardner LLP
Feb
14
2017
Federal Circuit Again Reverses PTAB Obviousness Determination Foley & Lardner LLP
Feb
23
2021
Early RCE Creates Gaps In Patent Term Adjustment Award Foley & Lardner LLP
Apr
28
2021
Carr v. Saul – Has the Court Tired of Issue Exhaustion? Potential Effects on Arthrex Foley & Lardner LLP
Jul
17
2017
Impact of TC Heartland on ANDA and Biosimilar Litigation Foley & Lardner LLP
Mar
1
2015
A Second Look At The Innovation Act Obviousness Type Double Patenting Statute Foley & Lardner LLP
Sep
27
2021
USPTO Revises Patent Bar Qualifications Foley & Lardner LLP
Apr
7
2015
Waiting On Sequenom: Pharma Patents Foley & Lardner LLP
Jan
13
2022
Choose the Words of Your Design Patent Applications Carefully Foley & Lardner LLP
May
2
2022
Supply Chain Shortages: How Wrongdoers Can Steal Your Secrets Foley & Lardner LLP
Nov
8
2017
Ready to Release a New Pharmaceutical? What to Think About When Selecting Your Drug Name Foley & Lardner LLP
Jun
27
2022
New Jersey Bill Would Significantly Limit – And Make Employers Pay For – Non-Compete Agreements Foley & Lardner LLP
Jun
30
2015
Federal Circuit Invalidates Another Diagnostic Patent Foley & Lardner LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins